Oscar Reig
Oncology Service OncologistResearch group
- Translational genomics and targeted therapies in solid tumours Accredited researcher (R3A)
Featured publications
-
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS)
Authors:Reference: Journal Of Clinical Oncology 2020. -
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer
Authors:Reference: International Journal Of Cancer 2019. -
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer-types.
Authors:Reference: Annals Of Oncology 2018. -
Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy
Authors:Reference: Oncoimmunology 2018. -
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Authors:Reference: British Journal Of Cancer 2017. -
The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
Authors:Reference: Oncology 2017. -
Corrigendum re: TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer [Eur Urol 2016;70:709-13]
Authors:Reference: European Urology 2017. -
Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study.
Authors:Reference: European Respiratory Journal 2017. -
TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer
Authors:Reference: European Urology 2016. -
Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients
Authors:Reference: Clinical Genitourinary Cancer 2016.
Featured Projects
-
Perfil molecular asociado al beneficio a la inmunoterapia en pacientes con cáncer de próstata hormonosensible: Estudios traslacionales asociados al ensayo clínico PROSTRATEGY
Principal investigator: Oscar Reig TorrasFunder: Fundació Clínic per a la Recerca Biomèdica (Sede o evento); Fundación SOGUGDuration: 01/01/2022 - 31/12/2024 -
Remodelación del microambiente tumoral mediante la modulación del secretoma para mejorar la respuesta a la inmunoterapia en el carcinoma renal de células claras
Funder: Fundació Clínic per a la Recerca Biomèdica (Sede o evento); Instituto de Salud Carlos IIIDuration: 01/01/2022 - 31/12/2024 -
Molecular and functional characterization of BAP1/PBRM1 double-mutant clear cell renal cell carcinoma.
Principal investigator: Oscar Reig TorrasFunder: UT Southwestern Medical Center (Sede o evento); Fundación SEOM / Fundación CRIS contral el càncerDuration: 01/04/2019 - 01/04/2020 -
Celular plasticity and immune profile and its relationship with therapeutic response in patients with metastatic prostate cancer.
Principal investigator: Jose Garcia CorbachoFunder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Instituto de Salud Carlos IIICode: PI18/00714Duration: 01/01/2019 - 01/01/2021 -
Exploratory study of the role of TMPRSS2-ERG expression and associated transcriptional profile in metastatic castration-sensitive prostate cancer patients treated with hormonal therapy and taxanes
Principal investigator: Oscar Reig TorrasFunder: Janssen-CilagDuration: 01/01/2018